The financial result missed the standing expectation. Six-month revenue was $1.503 million, including $494,000 in Q1, implying roughly $1.01 million of Q2 revenue versus a published consensus near $1.50 million. The filing provides no quarterly EPS figure, but the revenue gap is a clear miss for a company with limited commercial income.
| Metric | Q2 2026 | Prior comparison / expectation |
|---|---|---|
| Implied quarterly revenue | ~$1.01M | Published consensus ~$1.50M |
| Six-month revenue | $1.503M (Results for announcement to the market) | $1.174M in 2025; +28% (Results for announcement to the market) |
| Six-month loss after tax | $(51.675)M (Results for announcement to the market) | $(42.993)M in 2025; loss widened 20% (Results for announcement to the market) |
| Six-month net loss attributable to members | $(52.118)M (Results for announcement to the market) | $(42.698)M in 2025; loss widened 22% (Results for announcement to the market) |
| Q2 net operating cash outflow | $20.8M (Financial Results) | No published company target provided |
| Q2 R&D expense | $23.4M (Financial Results) | No published company target provided |
The clinical update was real progress, but mostly execution rather than a new efficacy signal. Anteris secured Medicare reimbursement eligibility for participating U.S. PARADIGM sites, enrolled and treated its first U.S. patients in May, and had recruitment active in the U.S., Denmark and the Netherlands. Those milestones improve trial feasibility, but the filing gives no enrollment count, completion timeline, or interim clinical result. (Q2 2026 Highlights; Business & Operations)
The most important positive was already partly known by the filing date. CMS coverage was received in April 2026 and U.S. recruitment began in May, so the quarter confirms that those steps occurred rather than introducing an unexpected catalyst. The new information is the continued expansion of sites and regulatory clearance in Canada and France. (Business & Operations; Q2 2026 Highlights)
The cost profile shows the trial is scaling faster than revenue. Q2 operating cash outflows reached $20.8 million and R&D expense was $23.4 million, driven by trial enrollment, manufacturing and quality infrastructure, validation work, and added clinical staff. That spending is consistent with advancing PARADIGM, but the filing does not provide cash on hand, runway, or financing plans, leaving funding needs difficult to assess. (Financial Results)
Net read: operationally constructive, financially a miss. The trial moved forward across reimbursement, recruitment, and regulatory fronts, but those gains were not accompanied by a quantified acceleration in enrollment or a new clinical readout. Against the published revenue expectation, the quarter lands as a Miss, with the worsening loss profile and heavy cash use outweighing the mostly anticipated execution milestones.
Read the original 8-K on SEC EDGAR ↗